Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2025ToxinsOpen Access

Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech Drugs

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDamiana ScuteriPMPaolo Martelletti

Discussion

Loading...

Member takes

Overview

This research examines genetic and epigenetic factors influencing chronic migraine treatment outcomes, suggesting potential pathways for enhanced therapies.

Key Points

  • Onabotulinumtoxin A is used for chronic migraine profylaxis, affecting neurotransmitter release in sensory neurons.
  • Genetic variants related to vascular regulation may influence migraine susceptibility and treatment responses.
  • Epigenetics is an emerging area of study, with limited research on its role in chronic migraine mechanisms.
  • Understanding CGRP's genetic and epigenetic influences could lead to improved treatment options for chronic migraine.

Cite This Study

Scuteri et al. (2025) studied this question.

synapsesocial.com/papers/689a0933e6551bb0af8ce504https://doi.org/10.3390/toxins17070355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CGRP and Migraine: Real World Insights and Future Therapeutic Directions2025
  2. 2Optimizing Migraine Therapy: A Comparative Review of Dosage and Tolerability of Calcitonin Gene Related Peptide Antagonists2025
  3. 3Exploring the epigenetic modifications of the RONS-TRPA1-CGRP axis in migraine pathophysiology2025
  4. 4Mechanisms of therapeutic action of monoclonal antibodies to the calcitonin gene-related peptide (CGRP) ligand-receptor system in migraine2025
  5. 5Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine2026